Niagen Bioscience, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Niagen Bioscience, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.42M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $99.60M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $83.57M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $72.05M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $67.45M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $59.26M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $46.29M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $31.56M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $21.20M | Mar 7, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.19M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $61.59M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $50.78M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $42.80M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $41.49M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $35.27M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $25.77M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $16.06M | Mar 10, 2020 |
| FY2017 | Dec 30, 2017 | $3.83M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $2.92M | Mar 15, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.38M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $8.55M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($4.94M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($16.54M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($27.13M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($19.93M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($32.15M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($33.32M) | Mar 10, 2020 |
| FY2017 | Dec 30, 2017 | ($8.82M) | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $2.14M | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.28M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $7.73M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($5.60M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($18.63M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($27.07M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($19.85M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($31.30M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($33.17M) | Mar 10, 2020 |
| FY2017 | Dec 30, 2017 | ($8.78M) | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | ($3.18M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.33M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $6.02M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $4.96M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $4.83M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $3.83M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $3.42M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $4.42M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $5.48M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $4.01M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $2.52M | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.50M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $12.11M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $7.12M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($15.10M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($24.16M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($10.60M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($20.44M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($20.91M) | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | ($9.80M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($2.94M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $743.0K | Mar 10, 2020 |
| FY2019 | Dec 31, 2018 | $1.32M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $1.17M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $1.50M | Mar 15, 2018 |
| FY2017 | Jan 2, 2016 | $525.2K | Mar 15, 2018 |
| FY2016 | Jan 3, 2015 | $123.1K | Mar 16, 2017 |
| FY2015 | Dec 28, 2013 | $137.3K | Mar 17, 2016 |
| FY2013 | Dec 29, 2012 | $24.6K | Mar 27, 2014 |
| FY2012 | Dec 31, 2011 | $150.7K | Mar 29, 2013 |
| FY2011 | Jan 1, 2011 | $169.1K | Mar 15, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.41M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $68.28M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $54.96M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $54.06M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $57.84M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $38.36M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $40.25M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $42.23M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $62.72M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $19.75M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.87M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $22.18M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $26.51M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $25.39M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $26.11M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $21.93M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $19.80M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $15.05M | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | $8.89M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $9.78M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.53M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $46.09M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $28.46M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $28.67M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $31.73M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $16.42M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $20.45M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $27.18M | Mar 12, 2021 |
| FY2019 | Dec 30, 2017 | $53.83M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $9.97M | Mar 7, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($164.53M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($181.91M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($190.46M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($185.49M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($168.95M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($141.83M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($121.90M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($89.75M) | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | ($56.60M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($45.22M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $44.50M | Mar 4, 2025 |
| FY2023 | Dec 31, 2023 | $27.20M | Mar 6, 2024 |
| FY2022 | Dec 31, 2022 | $20.30M | Mar 8, 2023 |
| FY2021 | Dec 31, 2021 | $28.22M | Mar 14, 2022 |
| FY2021 | Dec 31, 2020 | $16.70M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $18.81M | Mar 12, 2021 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jan 2, 2016 | $5.00M | Mar 17, 2016 |
| FY2014 | Jan 3, 2015 | $2.50M | Mar 19, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 14, 2022 |
| FY2017 | Dec 30, 2017 | 0 | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 15, 2018 |
| FY2017 | Jul 1, 2017 | 0 | Mar 15, 2018 |
| FY2017 | Apr 1, 2017 | 0 | Mar 15, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 14, 2022 |
| FY2017 | Dec 30, 2017 | 0 | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 15, 2018 |
| FY2017 | Jul 1, 2017 | 0 | Mar 15, 2018 |
| FY2017 | Apr 1, 2017 | 0 | Mar 15, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 79.71M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 77.33M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 74.98M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 74.57M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 68.13M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 61.88M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 59.56M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 55,089 | Mar 10, 2020 |
| FY2018 | Dec 30, 2017 | 54.70M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 37.54M | Mar 15, 2018 |